| 000 | 01741 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516031001.0 | ||
| 264 | 0 | _c20110603 | |
| 008 | 201106s 0 0 eng d | ||
| 022 | _a1326-5377 | ||
| 024 | 7 |
_a10.5694/j.1326-5377.2011.tb02979.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGrossmann, Mathis | |
| 245 | 0 | 0 |
_aBone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. _h[electronic resource] |
| 260 |
_bThe Medical journal of Australia _cMar 2011 |
||
| 300 |
_a301-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAbsorptiometry, Photon |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xadverse effects |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aDiphosphonates _xtherapeutic use |
| 650 | 0 | 4 |
_aExercise _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLife Style |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOsteoporosis _xchemically induced |
| 650 | 0 | 4 |
_aOsteoporotic Fractures _xdiagnosis |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHamilton, Emma J | |
| 700 | 1 | _aGilfillan, Christopher | |
| 700 | 1 | _aBolton, Damien | |
| 700 | 1 | _aJoon, Daryl Lim | |
| 700 | 1 | _aZajac, Jeffrey D | |
| 773 | 0 |
_tThe Medical journal of Australia _gvol. 194 _gno. 6 _gp. 301-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5694/j.1326-5377.2011.tb02979.x _zAvailable from publisher's website |
| 999 |
_c20696400 _d20696400 |
||